drugset
drugset / Trial / NCT06277752

A Study to Investigate the Pharmacokinetic/Pharmacodynamic Characteristics of IBI128(A New Xanthine Oxidase Inhibitor)

NCT06277752 ↗

Phase 1 Completed 30 enrolled Innovent Biologics (Suzhou) Co. Ltd.
NaSingle-groupOpen-labelTreatment

Summary

A Phase I study to evaluate the pharmacokinetic/pharmacodynamic characteristics,safety and tolerability of IBI128 after multidosing in Chinese health subjects.

Timeline

Start
2024-03-05
Primary completion
2024-03-16
Completion
2024-03-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Tigulixostat Small molecule 25 mg Oral
Subject Tigulixostat Small molecule 50 mg Oral
Subject Tigulixostat Small molecule 100 mg Oral
Subject Tigulixostat Small molecule 200 mg Oral
Subject Tigulixostat Small molecule 300 mg Oral

Indications

gout